Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.51 |
| ▸ | BCR | P11274 | 9/20 | 0.51 |
| ▸ | SRC | P12931 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 4/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152829 | 0.88 | ABL1 (0.51) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4384844 | 0.77 | JAK2 (0.63) | JAK2JAK3 | |
| SCHEMBL19847132 | 0.77 | ABL1 (0.56) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1938199 | 0.72 | TBK1 (0.42) | EGFR | |
| SCHEMBL23275803 | 0.70 | JAK2 (0.57) | JAK2JAK3 | |
| SCHEMBL29713621 | 0.70 | JAK2 (0.57) | JAK2JAK3 | |
| SCHEMBL20363185 | 0.69 | JAK2 (0.56) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2534029 | 0.69 | KIF11 (0.49) | PIK3CA | |
| SCHEMBL19847213 | 0.69 | JAK2 (0.57) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2944432 | 0.68 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | ABL1 3037/4885BCR 4756/4885SRC 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.